MedTrace Logo

Study for The Prevention Of Nausea in Cancer Patients Receiving Highly Emetogenic Cisplatin Based Chemotherapy

NCT00169572 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 492

Last updated 2010-05-10

No results posted yet for this study

Summary

This study was designed to assess the safety and efficacy of an investigational agent administered in addition to a standard anti-emetic regimen for the treatment of chemotherapy induced nausea and vomiting.

Conditions

  • Nausea and Vomiting
  • Chemotherapy-Induced

Interventions

DRUG

Aprepitant

DRUG

Ondansetron

DRUG

GW679769

DRUG

Dexamethasone

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials, MD · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-02-28

Countries

  • Argentina
  • Austria
  • Belgium
  • Chile
  • Croatia
  • Czechia
  • Hong Kong
  • Hungary
  • Italy
  • Mexico
  • Netherlands
  • Pakistan
  • Peru
  • Philippines
  • Poland
  • Romania
  • Singapore
  • Slovakia
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00169572 on ClinicalTrials.gov